Project 171064
Regulation of neuroinflammation and neuropathology in multiple sclerosis by the matrix metalloproteinase inducer, EMMPRIN
Regulation of neuroinflammation and neuropathology in multiple sclerosis by the matrix metalloproteinase inducer, EMMPRIN
Project Information
| Study Type: | Other Drug_Development |
| Therapeutic Area: | Neurology |
| Research Theme: | Biomedical |
| Disease Area: | multiple sclerosis |
| Data Type: | Canadian |
Institution & Funding
| Principal Investigator(s): | Yong, Voon W |
| Institution: | University of Calgary |
| CIHR Institute: | Neurosciences, Mental Health and Addiction |
| Program: | |
| Peer Review Committee: | Cell Biology & Mechanisms of Disease |
| Competition Year: | 2008 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Many factors contribute to the progression of multiple sclerosis (MS) including the expression of a family of proteins called matrix metalloproteinases (MMPs). Many MMPs are upregulated in MS lesions and it would be advantageous to switch these off. Dr. Yong will investigate an inducer of the expression of many MMPs, referred to as EMMPRIN. The research will focus on the expression of EMMPRIN in MS brain lesions, then address how EMMPRIN regulates the pathology of MS, and will further use an animal model of MS in order to examine whether inhibiting EMMPRIN would resolve the disease. Besides an understanding of the evolution of the MS disease process, this application may provide new insights into a potential new treatment of MS.
Research Characteristics
This project includes the following research characteristics:
Study Justification
"The research will focus on the expression of EMMPRIN in MS brain lesions, then address how EMMPRIN regulates the pathology of MS, and will further use an animal model of MS in order to examine whether inhibiting EMMPRIN would resolve the disease."
Novelty Statement
"Besides an understanding of the evolution of the MS disease process, this application may provide new insights into a potential new treatment of MS."
Methodology Innovation
investigating EMMPRIN as a therapeutic target in multiple sclerosis by studying its role in neuroinflammation and neuropathology